X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUN PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUN PHARMA FRESENIUS KABI ONCO./
SUN PHARMA
 
P/E (TTM) x 22.1 15.4 144.0% View Chart
P/BV x 3.1 3.6 86.1% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 FRESENIUS KABI ONCO.   SUN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUN PHARMA
Mar-16
FRESENIUS KABI ONCO./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,201 14.7%   
Low Rs79706 11.1%   
Sales per share (Unadj.) Rs37.7117.5 32.1%  
Earnings per share (Unadj.) Rs5.119.6 26.0%  
Cash flow per share (Unadj.) Rs6.723.8 28.2%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs42.5130.5 32.6%  
Shares outstanding (eoy) m158.232,406.60 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.48.1 41.6%   
Avg P/E ratio x25.048.7 51.3%  
P/CF ratio (eoy) x18.940.1 47.3%  
Price / Book Value ratio x3.07.3 40.9%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m20,1352,294,813 0.9%   
No. of employees `0001.214.7 7.8%   
Total wages/salary Rs m70347,971 1.5%   
Avg. sales/employee Rs Th5,176.219,169.8 27.0%   
Avg. wages/employee Rs Th610.43,253.0 18.8%   
Avg. net profit/employee Rs Th699.63,197.9 21.9%   
INCOME DATA
Net Sales Rs m5,963282,697 2.1%  
Other income Rs m186,170 0.3%   
Total revenues Rs m5,981288,867 2.1%   
Gross profit Rs m1,43083,239 1.7%  
Depreciation Rs m25810,135 2.5%   
Interest Rs m-264,769 -0.5%   
Profit before tax Rs m1,21674,505 1.6%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m-68-6,852 1.0%   
Tax Rs m3429,349 3.7%   
Profit after tax Rs m80647,159 1.7%  
Gross profit margin %24.029.4 81.5%  
Effective tax rate %28.112.5 224.2%   
Net profit margin %13.516.7 81.0%  
BALANCE SHEET DATA
Current assets Rs m5,102308,646 1.7%   
Current liabilities Rs m2,385132,477 1.8%   
Net working cap to sales %45.662.3 73.1%  
Current ratio x2.12.3 91.8%  
Inventory Days Days15083 180.9%  
Debtors Days Days11388 129.1%  
Net fixed assets Rs m5,148133,606 3.9%   
Share capital Rs m1582,407 6.6%   
"Free" reserves Rs m6,556266,909 2.5%   
Net worth Rs m6,732314,042 2.1%   
Long term debt Rs m95231,167 3.1%   
Total assets Rs m10,388542,196 1.9%  
Interest coverage x-45.816.6 -275.4%   
Debt to equity ratio x0.10.1 142.5%  
Sales to assets ratio x0.60.5 110.1%   
Return on assets %7.59.6 78.4%  
Return on equity %12.015.0 79.7%  
Return on capital %14.617.8 82.3%  
Exports to sales %74.514.0 532.0%   
Imports to sales %24.83.1 788.6%   
Exports (fob) Rs m4,44139,572 11.2%   
Imports (cif) Rs m1,4778,882 16.6%   
Fx inflow Rs m5,29842,171 12.6%   
Fx outflow Rs m1,77221,583 8.2%   
Net fx Rs m3,52520,588 17.1%   
CASH FLOW
From Operations Rs m1,27467,694 1.9%  
From Investments Rs m-1,204-44,549 2.7%  
From Financial Activity Rs m-196-19,243 1.0%  
Net Cashflow Rs m-1263,902 -3.2%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 9.6 23.0 41.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   42,599 133,026 32.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  MERCK LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS